


Parenteral Packaging conference



This year's *Parenteral Packaging conference* is scheduled for March 19–20 in Venice, Italy. Articles with this banner at the top of the page relate to this important meeting.

26




Regulatory Concerns Drive New Developments in Glass Packaging

Rebecca Stauffer, PDA

Find out what some of the speakers and program planning committee members behind the upcoming PDA *Parenteral Packaging* conference think is spurring development of new types of glass packaging.

Cover Art Illustrated by Katja Yount




An Overview of Container Closure Integrity

Considerations for Achieving an Optimal Performance Window for Container Closure Systems

Qingyu Zeng, PhD, West Pharmaceutical Services, Inc.

A typical container closure system has three major components: a rubber stopper, vial and aluminum seal. In order to satisfy mandatory patient safety requirements, container closure integrity must be ensured through a holistic consideration of many critical aspects.

III. InfoGraphic



36

United States and Europe Align on Glass

Find out how the U.S. Pharmacopeia has aligned with the European Pharmacopoeia around glass packaging.

The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—
contact the PDA Letter Managing Editor for details. © PDA 2019

PDA LETTER STAFF

Senior Director of Publishing
Walter Morris
(301) 656-5900, ext. 148
morris@pda.org

Managing Editor
Rebecca Stauffer
stauffer@pda.org

Graphic Designer
Katja Yount
yount@pda.org

PDA LETTER EDITORIAL COMMITTEE

Marcia Baroni
Eli Lilly & Company

Joanne Beck
Celgene

Walid El Azab
STERIS

Michael De Felippis, PhD
Eli Lilly

Mirko Gabriele
Patheon

Stephanie Gauling
DPS Engineering

Richard Hameister
Coherus Biosciences

Brian Hawkins, PhD
BioLife Solutions

Tamer Helmy, PhD
Microbial Vigilance

Zena Kaufman
ZGK Quality Consulting

Gwendolyn Lohr
Novo Nordisk

Frank Matos
SOFIE

Aaron Mertens
STERIS

Ajay Pazhayattil
Eurofins

Andiyanto Sutandar, PhD
HGP Asia Pte. Ltd.

Cecilia Turoff
Pfizer

Wendy Zwolenski Lambert
Novartis

Kelly Waldron
ValSource

ADVERTISING SALES

Vice President, Sales
David Hall
(301) 656-5900 ext. 160
hall@pda.org

EXECUTIVE STAFF

Richard Johnson
President & CEO
David Talmage
Sr. VP, Education

Tina Morris, PhD
VP, Scientific & Regulatory Affairs
Jennifer Bell
VP, Finance

Debbie Goldstein
VP, Marketing

David Hall
VP, Sales

Falk Klar, PhD
VP, PDA Europe

Molly Moir
VP, Programs & Meetings

Trevor Swan
Director, Membership & Chapters

PDA BOARD OF DIRECTORS

OFFICERS

Chair | Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect | Jette Christensen, PhD
Novo Nordisk

Treasurer | Michael Sadowski
Baxter Healthcare

Secretary | Steven Lynn
Lynn Consulting

Imm. Past Chair | Martin VanTrieste

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Joyce Bloomfield

Bettine Boltres, PhD
West

Veronique Davoust
Pfizer

Ghada Haddad
Merck

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates
Pfizer

Emma Ramnarine
Genentech/Roche

Anil Sawant, PhD
Merck & Co./Merck Sharp & Dohme

Melissa Seymour
Biogen

Departments

News & Notes

- 8 2019 PDA Board of Directors
- 9 Comment on PIC/S DI Guidance via PDA

People

- 10 Volunteer Spotlight | Friedrich von Wintzingerode
- 12 Chapter Update | India Chapter Gets Hands-On with CCI Tech
- 14 Photostream | PDA/FDA Joint Regulatory Conference; 13th Annual PDA Global Conference on Pharmaceutical Microbiology

Science

- 18 Science Snapshot | Co-Authors Team Up for Book Signing at PDA Micro; *Journal TOC*: Latest Research on Extraction/Leaching, Split-Cakes and More in Jan/Feb PDA Journal
- 19 Current Perspectives on the Monocyte Activation Test
- 22 Are You (And Pharma) Ready for the Future?


Regulatory

- 39 Regulatory Snapshot | *IG Corner*: Quality Metrics Still a Point of Discussion between Industry, U.S. FDA
- 41 Innovative Tech Drives Drug Shortage Solutions

Voices of PDA

- 44 President's Message | PDA Adapts to Changing Future
- 46 Voices of the Board | Embracing the Future of Cell and Gene Therapies

Digital Exclusives

- > **On the Issue | Big Data** 
Roche's Aaron Goerke talks about what big data means for pharma manufacturing.
- > **Holistic Verification Requires a New Mindset**
CSL Behring's David Hubmayr explains why holistic verification is key to manufacturing drug products in an increasingly patient-centric world.
- > **Amsterdam Move Reflects Larger Trend**
EMA is not the only thing moving to Amsterdam!

pda.org/letter

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org

PDA EUROPE — AM BORSIGTURM 60

Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

2019 PDA Annual Meeting



Discover the latest advancements in parenteral manufacturing at the 2019 PDA Annual Meeting by reading through our special Annual Meeting supplement!

20

PUPSIT & the Proposed Annex 1 Revision

Hal Baseman, ValSource

Since its publication in December 2017, the proposed Annex 1 revision has been much discussed. As coleader of the team that prepared PDA's comments on the revision, I am intimately familiar with the intricacies of the document. As such, I want to share some thoughts on the revision, culminating in four pieces of advice concerning one of the most debated points of contention within Annex 1.


Cover Art Illustrated by Katja Yount

InfoGraphic

28

Annex 1 Ready or Not?

The PDA Letter conducted an informal survey last year to ascertain how prepared PDA members are for the proposed Annex 1 revision.



The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—contact the PDA Letter Managing Editor for details. © PDA 2019

PDA LETTER STAFF

Senior Director of Publishing
Walter Morris
(301) 656-5900, ext. 148
morris@pda.org

Managing Editor
Rebecca Stauffer
stauffer@pda.org

Graphic Designer
Katja Yount
yount@pda.org

PDA LETTER EDITORIAL COMMITTEE

Marcia Baroni
Eli Lilly & Company

Joanne Beck
Celgene

Walid El Azab
STERIS

Michael De Felippis, PhD
Eli Lilly

Mirko Gabriele
Patheon

Stephanie Gauling
DPS Engineering

Richard Hameister
Coherus Biosciences

Brian Hawkins, PhD
BioLife Solutions

Tamer Helmy, PhD
Microbial Vigilance

Zena Kaufman
ZGK Quality Consulting

Gwendolyn Lohr
Novo Nordisk

Frank Matos
SOFIE

Aaron Mertens
STERIS

Ajay Pazhayattil
Eurofins

Andiyanto Sutandar, PhD
HGP Asia Pte. Ltd.

Cecilia Turoff
Pfizer

Wendy Zwolenski Lambert
Novartis

Kelly Waldron
ValSource

ADVERTISING SALES

Vice President, Sales
David Hall
(301) 656-5900 ext. 160
hall@pda.org

EXECUTIVE STAFF

Richard Johnson
President & CEO

David Talmage
Sr. VP, Education

Tina Morris, PhD
VP, Scientific & Regulatory Affairs

Jennifer Bell
VP, Finance

Debbie Goldstein
VP, Marketing

David Hall
VP, Sales

Falk Klar, PhD
VP, PDA Europe

Molly Moir
VP, Programs & Meetings

Trevor Swan
Director, Membership & Chapters

PDA BOARD OF DIRECTORS

OFFICERS

Chair | Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect | Jette Christensen, PhD
Novo Nordisk

Treasurer | Michael Sadowski
Baxter Healthcare

Secretary | Steven Lynn
Lynn Consulting

Imm. Past Chair | Martin VanTrieste
Civica Rx

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Joyce Bloomfield

Bettine Boltres, PhD
West

Veronique Davoust
Pfizer

Ghada Haddad
Merck

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates

Emma Ramnarine
Genentech/Roche

Anil Sawant, PhD
Merck & Co./Merck Sharp & Dohme

Melissa Seymour
Biogen

Departments

News & Notes

8 Visit the Redesigned PDA Website

People

10 Volunteer Spotlight | Christine Bui

12 Chapter Update | Chapter Meeting Validates Data Integrity as Key Issue

14 Photostream | Project Management in the Pharmaceutical Industry; PDA Visitors

Science

16 Science Snapshot | Interest Group Corner: Lifecycle Management a Key Topic for Vaccines Interest Group at 2018 PDA/FDA JRC

17 Response to "Standing Guard"

19 Take C> Supply Challenges by the Horn

Regulatory

31 Global Regulators Partner for Greater Patient Access

34 Thanks for the Warning Letter: Part II

Voices of PDA

38 Voices of the Board | Chapters: Another Way to Connect

Digital Exclusives

> Alternative to LAL Gains Ground

As alternatives to the traditional LAL assay enter the market, what does this mean for the industry?

> Growth Promotion Testing for EM

Why are reference materials critical for environmental monitoring?

pda.org/letter

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org

PDA EUROPE — AM BORSIGTURM 60

Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

20

Industry Eyes Future of Visual Inspection

Five Critical Areas of Concern Draw Attention of Pharma Industry

John Shabushnig, PhD, Insight Pharma Consulting; Markus Lankers, PhD, MIBIC; John Ayres, MD, Pharma Safety Solutions; Roy Cherris, Bridge Associates; Robert Miller, Pfizer; Romain Veillon, GSK Vaccines; and Rick Watson, Merck

It goes without saying that visual inspection is critical to parenteral manufacturing. All units produced must be inspected to ensure a high level of quality assurance. Visual inspection can be performed with the human eye by a trained inspector under controlled conditions or via automation using advanced camera and computer technology.

Cover photo courtesy of Antares Vision. This photo depicts the company's Visual Rotating Inspector machine


28 The Challenges of Visually Inspecting IV Bags

Florian Krickl, Vitronic

Is there a common technical standard for automated visual inspection in difficult-to-inspect parenteral products? Talk with any quality manager or project engineer in the pharma manufacturing sector and they will tell you that there are a number of processes where inspection results often do not meet the expectations. As long as there is no independent standard defining the quality of automated visual inspection, however, inspection results can vary significantly case by case. This is a particular concern for IV bags.



InfoGraphic



32

Can We Achieve “0” Defects for Visible Particles?

Find out what can be done to accomplish this challenging goal in the latest PDA Letter InfoGraphic!

Big Data is Here to Stay

2018 PDA Manufacturing Intelligence Workshop Commands a Crowd

Aaron Goerke, PhD, F. Hoffmann-La Roche AG, and Michele D'Alessandro, Merck & Company, Inc.

Implementing big data within pharmaceutical manufacturing will require extensive collaboration. Fortunately, a 2018 PDA workshop suggests this is possible.

34



The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—
contact the PDA Letter Managing Editor for details. © PDA 2019

Departments

News & Notes

- 8 PDA Welcomes Ruth Miller
- 9 Board of Directors Nominations Needed
- 9 PDA Opens Asia Pacific HQ

People

- 10 Volunteer Spotlight | Kim Sobien
- 12 Chapter Update | Student Chapter Gains Stem Cell Insights

Science

- 14 Science Snapshot | New Datwyler Site Showcases Flexible Manufacturing; Journal TOC: Read the Latest Aseptic Processing Research in the March/April PDA Journal
- 16 Technology Column | Viruses on the Surface
- 18 Biopharma Offers New Opportunities
- 19 Can the Power of Viruses be Harnessed for Good?

Regulatory

- 39 PDA Comments | Eyeing Visual Inspection of Visible Particles
- 41 Vaccines, Biosimilars Share Commonalities
- 42 Implementation Proves Parametric Release Possible

Voices of PDA

- 46 Voices of the Board | Another Year of Reg Collaboration

Digital Exclusives

> **On the Issue | P. Acnes in an Aerobic Process** 
Merck's **Kenneth Boone** covers recovery of anaerobic microorganisms from an aerobic aseptic process simulation.

> **Change is in the Air for Packaging Components**
West's **Cathy Zhao** offers her perspective on the latest packaging trends.

pda.org/letter

PDA LETTER STAFF

Senior Director of Publishing
Walter Morris
(301) 656-5900, ext. 148
morris@pda.org

Managing Editor
Rebecca Stauffer
stauffer@pda.org

Graphic Designer
Katja Yount
yount@pda.org

PDA LETTER EDITORIAL COMMITTEE

Marcia Baroni
Eli Lilly & Company

Joanne Beck
Celgene

Walid El Azab
STERIS

Mirko Gabriele
Patheon

Stephanie Gaulding
DPS Engineering

Richard Hameister
Coherus Biosciences

Brian Hawkins, PhD
Pluristyx Inc.

Tamer Helmy, PhD
Alcon

Zena Kaufman
ZGK Quality Consulting

Gwendolyn Lohr
Novo Nordisk

Frank Matos
SOFIE

Aaron Mertens
STERIS

Ajay Pazhayattil
Eurofins

Andiyanto Sutandar, PhD
HGP Asia Pte. Ltd.

Cecilia Turoff
Pfizer

Wendy Zwolenski Lambert
Novartis

Kelly Waldron
ValSource

ADVERTISING SALES

Video President, Sales
David Hall
(301) 656-5900 ext. 160
hall@pda.org

EXECUTIVE STAFF

Richard Johnson
President & CEO

David Talmage
VP, Education

Tina Morris, PhD
VP, Scientific & Regulatory Affairs

Jennifer Bell
VP, Finance

Debbie Goldstein
VP, Marketing

David Hall
VP, Sales

Falk Klar, PhD
VP, PDA Europe

Molly Moir
VP, Programs & Meetings

Trevor Swan
Director, Membership & Chapters

PDA BOARD OF DIRECTORS

OFFICERS

Chair | Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect | Jette Christensen, PhD
Novo Nordisk

Treasurer | Michael Sadowski
Baxter Healthcare

Secretary | Steven Lynn
Lynn Consulting

Imm. Past Chair | Martin VanTrieste
Civica Rx

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Joyce Bloomfield

Bettine Boltres, PhD
West

Veronique Davoust
Pfizer

Ghada Haddad
Merck

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates
Pfizer

Emma Ramnarine
Genentech/Roche

Anil Sawant, PhD
Merck & Co./Merck Sharp & Dohme

Melissa Seymour
Biogen

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org



PDA EUROPE — AM BORSIGTURM 60

Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org

22



The Pharmacopeia in the 21st Century Pharmacopeias Move to Modernize in Changing Times

Susanne Keitel, EDQM

Maintaining a comfortable state of health has always been a major human preoccupation. By the dawn of the first millennium, this was manifested in *De Materia Medica*, generally considered to be the earliest example of a pharmacopoeia. This treatise compiled contemporary tried and tested herbal and other remedies, methods for their preparation and their effects on patients. Fast forward two thousand years and the world has changed entirely and, with it, attitudes about health and well-being.

Cover Art Illustrated by Katja Yount

28



Future Lies in Continuous Manufacturing Technology

What do the Global Regulators and Pharmacopeias Have to Say?

Bei Ma, Pinea Group

In recent years, the pharmaceutical manufacturing leaders have been exploring innovative and new technical solutions to achieve better quality, improve productivity and operational efficiency, increase process throughput and yields.

Advancements in technologies such as, digitalization, artificial intelligence and machine learning, 3D printing, precision medicine, automation, augmented and virtual reality, will shape the pharmaceutical industry over the next five to ten years.


Growth Promotion Testing For EM

Reference Materials Critical for Ensuring Effective Environmental Monitoring Tests

Brendan Tindall, biomerieux, and Graham Vesey, Regeneus

Growth promotion testing of culture media is an important part of microbiological testing in support of pharmaceutical quality. The growth promotion test is a quality control requirement that confirms the ability of a new batch of media to support growth of a predetermined selection of representative microorganisms.

30



InfoGraphic

34

Avoid These 5 SOP Pitfalls

Learn what mistakes to avoid in order to ensure an effective SOP for your GMP operations.



The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—
contact the PDA Letter Managing Editor for details. © PDA 2019

PDA LETTER STAFF

Senior Director of Publishing
Walter Morris
(301) 656-5900, ext. 148
morris@pda.org

Managing Editor
Rebecca Stauffer
stauffer@pda.org

Graphic Designer
Katja Yount
yount@pda.org

PDA LETTER EDITORIAL COMMITTEE

Marcia Baroni
Eli Lilly & Company

Joanne Beck
Celgene

Walid El Azab
STERIS

Mirko Gabriele
Patheon

Stephanie Gaulding
DPS Engineering

Richard Hameister
Coherus Biosciences

Brian Hawkins, PhD
Pluristyx Inc.

Tamer Helmy, PhD
Alcon

Zena Kaufman
ZGK Quality Consulting

Gwendolyn Lohr
Novo Nordisk

Frank Matos
SOFIE

Aaron Mertens
STERIS

Ajay Pazhayattil
Eurofins

Andiyanto Sutandar, PhD
HGP Asia Pte. Ltd.

Cecilia Turoff
Pfizer

Wendy Zwolenski Lambert
Novartis

Kelly Waldron
ValSource

ADVERTISING SALES

vice President, Sales
David Hall
(301) 656-5900 ext. 160
hall@pda.org

EXECUTIVE STAFF

Richard Johnson
President & CEO

David Talmage
Sr. VP, Education

Tina Morris, PhD
VP, Scientific & Regulatory Affairs

Jennifer Bell
VP, Finance

Debbie Goldstein
VP, Marketing

David Hall
VP, Sales

Falk Klar, PhD
VP, PDA Europe

Molly Moir
VP, Programs & Meetings

Trevor Swan
Director, Membership & Chapters

PDA BOARD OF DIRECTORS

OFFICERS

Chair | Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect | Jette Christensen, PhD
Novo Nordisk

Treasurer | Michael Sadowski
Baxter Healthcare

Secretary | Steven Lynn
Lynn Consulting

Imm. Past Chair | Martin VanTrieste
Civica Rx

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Joyce Bloomfield

Bettine Boltres, PhD
West

Veronique Davoust
Pfizer

Ghada Haddad
Merck

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates
Pfizer

Emma Ramnarine
Genentech/Roche

Anil Sawant, PhD
Merck & Co./Merck Sharp & Dohme

Melissa Seymour
Biogen

Departments

News & Notes

- 8 Jack Cole, In Memoriam
- 9 The 2018 PDA Letter Article of the Year

People

- 10 Volunteer Spotlight | Andiyanto Sutandar
- 12 Chapter Update | NE Election Results Revealed at Cold Storage Event
- 15 Tools for Success | 4 Simple Strategies for Overcoming Stress
- 16 Photostream | PUPSIT Testing; Cryopreservation Standard Task Force

Science

- 18 Science Snapshot | PDA Addresses LER in TR, Forthcoming Book; Journal Top 10: Particulate Papers Dominate PDA Journal Views for February
- 19 Technology | *B. cepacia*: What is it and Why is it a Concern?

Regulatory

- 37 Regulatory Snapshot | Quality Systems Interest Group Expands Activities
- 38 PDA Comments | Clarity Needed on CMC Guidance for C> Proposed Change for RCR Language
- 40 Data Integrity Journey Has Only Just Begun
- 43 Deep Dive into Biosimilars Continues

Voices of PDA

- 46 Voices of the Board | Advancing Cell and Gene Therapies

Digital Exclusives

- > Industry and Regulators Convene to Address Vaccines Challenges
Read a summary of last year's Vaccines conference in this longform article!

pda.org/letter

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org

PDA EUROPE — AM BORSIGTURM 60

Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org


Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

4th PDA Europe Annual Meeting



What does the future hold for parenteral manufacturing in Europe? Find out by reading through our special section highlighting the 4th PDA Europe Annual Meeting!

26



Highly Potent APIs Balancing Patient and Operator Safety

Rebecca Stauffer, PDA

When contamination control comes up as a topic of discussion at a PDA conference the conversation usually concerns how to protect product from potential contamination. But what about the operator?

Cover Art Illustrated by Katja Yount

InfoGraphic



Technology Transfer Failure to Communicate?

Earlier this year, PDA conducted a survey on tech transfer. The results were showcased at the 2019 PDA Annual Meeting. Check out some highlights from the survey.

The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—
contact the PDA Letter Managing Editor for details. © PDA 2019

PDA LETTER STAFF

Senior Director of Publishing
Walter Morris
(301) 656-5900, ext. 148
morris@pda.org

Managing Editor
Rebecca Stauffer
stauffer@pda.org

Graphic Designer
Katja Yount
yount@pda.org

PDA LETTER EDITORIAL COMMITTEE

Marcia Baroni
Eli Lilly & Company

Joanne Beck
Celgene

Walid El Azab
STERIS

Mirko Gabriele
Patheon

Stephanie Gaulding
DPS Engineering

Richard Hameister
Coherus Biosciences

Brian Hawkins, PhD
Pluristyx Inc.

Tamer Helmy, PhD
Alcon

Zena Kaufman
ZGK Quality Consulting

Gwendolyn Lohr
Novo Nordisk

Frank Matos
SOFIE

Aaron Mertens
STERIS

Ajay Pazhayattil
Eurofins

Andiyanto Sutandar, PhD
HGP Asia Pte. Ltd.

Cecilia Turoff
Pfizer

Wendy Zwolenski Lambert
Novartis

Kelly Waldron
ValSource

ADVERTISING SALES

Vice President, Sales
David Hall
(301) 656-5900 ext. 160
hall@pda.org

EXECUTIVE STAFF

Richard Johnson
President & CEO

David Talmage
Sr. VP, Education

Tina Morris, PhD
VP, Scientific & Regulatory Affairs

Jennifer Bell
VP, Finance

Debbie Goldstein
VP, Marketing

David Hall
VP, Sales

Falk Klar, PhD
VP, PDA Europe

Molly Moir
VP, Programs & Meetings

Trevor Swan
Director, Membership & Chapters

PDA BOARD OF DIRECTORS

OFFICERS

Chair | Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect | Jette Christensen, PhD
Novo Nordisk

Treasurer | Michael Sadowski
Baxter Healthcare

Secretary | Steven Lynn
Lynn Consulting

Imm. Past Chair | Martin VanTriest
Civica Rx

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Joyce Bloomfield

Bettine Boltres, PhD
West

Veronique Davoust
Pfizer

Ghada Haddad
Merck

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates
Lachman Consultant Services, Inc.

Emma Ramnarine
Genentech/Roche

Anil Sawant, PhD
Merck & Co./Merck Sharp & Dohme

Melissa Seymour
Biogen

Departments

News & Notes

8 2019 PDA Honor Awards

People

10 Volunteer Spotlight | Dawn Downey, PhD

12 Chapter Update | Building an Efficient QRM Strategy

14 Photostream | PDA PQS for PACs Quality Leaders

17 Eye on Education | PDA Expands Course Offerings in India

Science

18 Science Snapshot | Journal TOC: Upcoming PDA Journal Includes Technology Article on Surface Steam Sterilization Process

20 A Patient's Life Depends on Product Quality

Regulatory

34 PDA Comments | Drug Storage Regulations in Plain Language

35 Reclaim Efficiency Amid Serialization Nightmares

Voices of PDA

38 Voices of the Board | Collaboration Makes Things Easier!

Digital Exclusives

> **On the Issue | Controlling Contamination and Cross-Contamination** ▶
SKAN's **Richard Denk** discusses EU requirements to prevent cross-contamination at the 2019 PDA Annual Meeting

> **On the Issue | Implementing a Completely Closed, Robotic Isolator for Flexible Filling** ▶
Emergent's **Kevin Gadiant** provides insights on implementation of a gloveless, robotic isolator

> **Air Bubbles versus Transparent Particles**
Find out how to differentiate between the two during automated visual inspection

pda.org/letter

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org

PDA EUROPE — AM BORSIGTURM 60

Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

26

Gloveless Isolators Offer Speedy Throughput

Jim Akers, PhD, Akers Kennedy and Associates

If the reader thought this was going to be another commentary on the impact of humans on contamination and the elimination of direct interventions, they are going to be surprised. Automated, gloveless aseptic technologies are a logical progression as our field moves into the 21st century.

Cover Photo by Zora Zhuang



30

Aseptic Technology Advances to the Next Level

A Review of Four Technologies Used to Reduce Operator Interventions in Aseptic Manufacturing

Subrata Chakraborty, Cipla

The pharmaceutical industry has never been a rapid pioneer in adopting new technologies, preferring instead to evolve slowly and consciously.

InfoGraphic

34

Isolators Trending for Manufacturers

Check out results from PDA's 2017 aseptic processing survey specific to isolators.



The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—
contact the PDA Letter Managing Editor for details. © PDA 2019

PDA LETTER STAFF

Senior Director of Publishing
Walter Morris
(301) 656-5900, ext. 148
morris@pda.org

Managing Editor
Rebecca Stauffer
stauffer@pda.org

Graphic Designer
Katja Yount
yount@pda.org

PDA LETTER EDITORIAL COMMITTEE

Marcia Baroni
Eli Lilly & Company

Joanne Beck
Celgene

Walid El Azab
STERIS

Mirko Gabriele
Patheon

Stephanie Gaulding
Pharmatech Associates

Richard Hameister
Coherus Biosciences

Brian Hawkins, PhD
Pluristyx Inc.

Tamer Helmy, PhD
Alcon

Zena Kaufman
ZGK Quality Consulting

Gwendolyn Lohr
Novo Nordisk

Frank Matos
SOFIE

Aaron Mertens
STERIS

Ajay Pazhayattil
Eurofins

Andiyanto Sutandar, PhD
HGP Asia Pte. Ltd.

Cecilia Turoff
Pfizer

Wendy Zwolenski Lambert
Novartis

Kelly Waldron
ValSource

ADVERTISING SALES

Vice President, Sales
David Hall
(301) 656-5900 ext. 160
hall@pda.org

EXECUTIVE STAFF

Richard Johnson
President & CEO
David Talmage
Sr. VP, Education

Tina Morris, PhD
VP, Scientific & Regulatory Affairs

Jennifer Bell
VP, Finance

Debbie Goldstein
VP, Marketing

David Hall
VP, Sales

Falk Klar, PhD
VP, PDA Europe

Molly Moir
VP, Programs & Meetings

Trevor Swan
Director, Membership & Chapters

PDA BOARD OF DIRECTORS

OFFICERS

Chair | Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect | Jette Christensen, PhD
Novo Nordisk

Treasurer | Michael Sadowski
Baxter Healthcare

Secretary | Steven Lynn
Lynn Consulting

Imm. Past Chair | Martin VanTrieste
Civica Rx

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Joyce Bloomfield

Bettine Boltres, PhD
West

Veronique Davoust
Pfizer

Ghada Haddad
Merck

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates
Lachman Consultant Services, Inc.

Emma Ramnarine
Genentech/Roche

Anil Sawant, PhD
Merck & Co./Merck Sharp & Dohme

Melissa Seymour
Biogen

Departments

News & Notes

- 8 Share Your History with PDA
- 9 5 PDA Leaders Recognized by Trade Publication
- 9 Talk Highlights Personal Impact of Cell Therapies

People

- 10 Volunteer Spotlight | Brian J. Hawkins
- 12 Chapter Update | Cell and Gene Manufacturing Grows in Singapore
- 14 Photostream | 2019 PDA Annual Meeting; 2019 PDA Visual Inspection Forum

Science

- 18 **Science Snapshot | Interest Group Corner:** Manufacturing Plants Must Transform Aging Facilities to Alleviate Drug Shortage Concerns
Journal Top 10: Check Out the Latest Research on Continuous EM in the PDA Journal!
- 19 **Technology** | New ISO Standard Available for Water Systems
- 23 Rapid Micro Methods Carry Potential

Regulatory

- 36 **Comments** | Ph. Eur. Tackles Endotoxin Alternative rFC
- 39 U.S. FDA Rep Offers Overview on Visible Particulates
- 42 The Role of Project Managers in Pharma

Voices of PDA

- 46 **Voices of the Board** | PDA Leading Future of Biopharma

Digital Exclusives

- > **On the Issue** | USP <1207> and the Future of CCI Testing 
Diane Paskiet of West Pharmaceutical Services discusses the impact of <1207> on container closure integrity testing.

pda.org/letter

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org

PDA EUROPE — AM BORSIGTURM 60


Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org

PDA/FDA Joint Regulatory Conference

Learn what to expect at the 2019 PDA/FDA Joint Regulatory Conference in our special section.



DATA INTEGRITY



26

U.S. FDA Continues Data Integrity Focus A Review of U.S. Regulations on cGMP and Data Integrity

Lina Genovesi

The U.S. FDA continues to inspect pharmaceutical facilities for compliance with its cGMP regulations, and as a result of these inspections, has issued numerous warning letters citing several significant violations of cGMP regulations involving data integrity.

32

Follow the Audit Trail Breadcrumbs

Audit Trail Reviews Crucial for Maintaining Data Integrity

Ann Milliman, Baxter Healthcare Corporation

Data integrity is a hot topic for the U.S. FDA and other global regulatory agencies. Two crucial aspects, in particular, have been cited by regulators: audit trails and audit trail reviews.

36

New Technology Meets Old Data Integrity Challenges

Kir Henrici, The Henrici Group, Monica Cahilly, Green Mountain Quality Assurance, and Peter Baker, Green Mountain Quality Assurance

The ecosystem of life science data has experienced a seismic shift. Industry 4.0, the Internet of Things and next generation intelligence have enabled unprecedented capabilities in using data to support product development, process excellence, compliance and innovation. We are now in a new era suffused with promise for health and well-being.

InfoGraphic

40

PAC iAMSM MAN



Handling post-approval changes (PAC) can feel like an unending game of varying regulatory requirements. But following the ICH quality guidelines and ensuring robust quality systems can help achieve PAC goals.



The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—
contact the PDA Letter Managing Editor for details. © PDA 2019

Departments

News & Notes

- 8 PDA In the News
- 9 PDA TRI Wall Acknowledges Suppliers' Support

People

- 10 Volunteer Spotlight | Laurie Masiello
- 12 Chapter Update | More than Volcanoes or Solar System Models
- 13 Chapter Update | Chapter Offers Coffee with PDA President
- 14 Photostream | 2019 PDA Cell and Gene Therapy Conference; Capital Area Chapter Meet & Greet Networking Event
- 15 Eye on Education | PDA Aseptic Processing Course Instructors Go Global

Science

- 16 Summer Reading
- 22 Science Snapshot | Journal TOC: Study Looks at Endotoxin Testing for Snake Bite Antivenoms Produced Using Horse Plasma
- 23 Future of Packaging on Display at Stevanato Tour
- 24 Air Bubbles versus Transparent Particles


Regulatory

- 43 Comments | Full Support for WHO WFI Guidance
- 44 A Weeklong Look at Quality Risk Management
- 47 Foreign Particles in Bull's Eye of Global Reg Agencies
- 48 Holistic Verification Requires a New Mindset

Voices of PDA

- 50 Voices of the Board | Common Goals Make Everyone Stronger

Digital Exclusives

- > **On the Issue** | Here They Come: Pharma Young Professionals 
West Pharma's **Amy Kim** and Biogen's **Maria Bednar** discuss their Young Professionals presentations at the 2019 PDA Annual Meeting.
- > **Excipients' Attributes Crucial for Parenteral Preparations**
Learn why quality attributes are important for the excipients used in our industry.
- > **SoCal Student Chapter Keeps Busy**
Find out what the PDA Southern California's student chapter has been up to!

pda.org/letter

PDA LETTER STAFF

Senior Director of Publishing
Walter Morris
(301) 656-5900, ext. 148
morris@pda.org

Managing Editor
Rebecca Stauffer
stauffer@pda.org

Graphic Designer
Katja Yount
yount@pda.org

PDA LETTER EDITORIAL COMMITTEE

Marcia Baroni
Eli Lilly & Company

Joanne Beck
Celgene

Walid El Azab
STERIS

Mirko Gabriele
Patheon

Stephanie Gaulding
Pharmatech Associates

Richard Hameister
Coherus Biosciences

Brian Hawkins, PhD
Pluristyx Inc.

Tamer Helmy, PhD
Alcon

Zena Kaufman
ZGK Quality Consulting

Gwendolyn Lohr
Novo Nordisk

Frank Matos
SOFIE

Aaron Mertens
STERIS

Ajay Pazhayattil
Eurofins

Andiyanto Sutandar, PhD
HGP Asia Pte. Ltd.

Cecilia Turoff
Pfizer

Wendy Zwolenski Lambert
Novartis

Kelly Waldron
ValSource

ADVERTISING SALES

vice President, Sales
David Hall
(301) 656-5900 ext. 160
hall@pda.org

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

EXECUTIVE STAFF

Richard Johnson
President & CEO

David Talmage
VP, Education

Tina Morris, PhD
VP, Scientific & Regulatory Affairs

Jennifer Bell
VP, Finance

Debbie Goldstein
VP, Marketing

David Hall
VP, Sales

Falk Klar, PhD
VP, PDA Europe

Molly Moir
VP, Programs & Meetings

Trevor Swan
Director, Membership & Chapters

PDA BOARD OF DIRECTORS

OFFICERS

Chair | Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect | Jette Christensen, PhD
Novo Nordisk

Treasurer | Michael Sadowski
Baxter Healthcare

Secretary | Steven Lynn
Lynn Consulting

Imm. Past Chair | Martin VanTrieste
Civica Rx

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Joyce Bloomfield

Bettine Boltres, PhD
West

Veronique Davoust
Pfizer

Ghada Haddad
Merck

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates
Lachman Consultant Services, Inc.

Emma Ramnarine
Genentech/Roche

Anil Sawant, PhD
Merck & Co./Merck Sharp & Dohme

Melissa Seymour
Biogen

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org

PDA EUROPE — AM BORSIGTURM 60

Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org

28



Lifecycle Approach Wipes Away Cleaning Validation Concerns

Raji Vathyam

Cleaning validation is a perpetual undertaking for multiproduct drug manufacturing companies, particularly those with dynamic product profiles and frequently changing commercial needs. With rising demands for complex molecules or highly potent drugs, manufacturers now must continuously invest in new technologies such as containment systems, which offer protection to both operators and finished products.

Cover Photo by Katja Yount

32




Human Error Causes OOS Investigation

One Company's Experience with Determining Root Cause for an Endotoxin Testing Failure

Rebecca Stauffer and Madeline Cusick, PDA

Testing failures are not unheard of in the industry. Routine samples that normally pass specification can, out of the blue, suddenly fail.

InfoGraphic



36

Endotoxin Control in Another Industry

Find Out How an Operating Room Improved Their Endotoxin Control

Endotoxin control is a major concern for pharmaceutical microbiologists. Did you know it is also an issue in operating theaters? A ten-year study of endotoxin-retentive ultrafilters used for reverse osmosis (RO) plants in an operating theater was highlighted last year in the *PDA Journal of Pharmaceutical Science and Technology*.

The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—
contact the PDA Letter Managing Editor for details. © PDA 2019

Departments

News & Notes

- 8 Help Shape the Future of Your Association
- 9 PDA Remembers Edmund “Ed” Fitzgerald

People

- 10 Volunteer Spotlight | Kir Henrici
- 12 Chapter Update | Ireland Chapter Addresses Annex 1 Revision
- 15 Volunteer Opportunities Abound!
- 17 Eye on Education | Students Enthused About PDA Courses in India
- 18 Photostream | 4th PDA Europe Annual Meeting

Science

- 20 **Science Snapshot | In Print:** Validation Requirements for Cleaning and Sanitization Practices
Journal Preview: More on Low Endotoxin Recovery in the September/October PDA Journal!
- 22 ISO 22519: A Flawed and Counterproductive Standard
- 26 Ready for the Pharma of Tomorrow?


Regulatory

- 39 PDA Comments | Concerns About USP <1235> Revision
- 41 Why is the EU Medical Device Regulation So Critical?
- 43 Supporting the Quality Risk Management Framework
- 44 Regulators, Compendia Eye Components

Voices of PDA

- 46 Voices of the Board | Your Local Connection to PDA

Digital Exclusives

- > **On the Issue | Here They Come: Pharma Young Professionals**  West Pharma's **Amy Kim** and Biogen's **Maria Bednar** discuss their Young Professionals presentations at the 2019 PDA Annual Meeting.
- > **Another Perspective on rFC**
Lonza's **Allen Burgenson** comments on recent coverage of alternative endotoxin testing technologies.
- > **SE Chapter Helps Students Build Bridge to Future**
Learn more about the new student chapter affiliated with the Southeast Chapter!

pda.org/letter

PDA LETTER STAFF

Senior Director of Publishing
Walter Morris
(301) 656-5900, ext. 148
morris@pda.org

Managing Editor
Rebecca Stauffer
stauffer@pda.org

Graphic Designer
Katja Yount
yount@pda.org

PDA LETTER EDITORIAL COMMITTEE

Marcia Baroni
Eli Lilly & Company

Joanne Beck
Celgene

Walid El Azab
STERIS

Mirko Gabriele
Patheon

Stephanie Gaulding
Pharmatech Associates

Richard Hameister
Coherus Biosciences

Brian Hawkins, PhD
Pluristyx Inc.

Tamer Helmy, PhD
Alcon

Zena Kaufman
ZGK Quality Consulting

Gwendolyn Lohr
Novo Nordisk

Frank Matos
SOFIE

Aaron Mertens
STERIS

Ajay Pazhayattil
Eurofins

Andiyanto Sutandar, PhD
HGP Asia Pte. Ltd.

Cecilia Turoff
Pfizer

Wendy Zwolenski Lambert
Novartis

Kelly Waldron
ValSource

ADVERTISING SALES

Video President, Sales
David Hall
(301) 656-5900 ext. 160
hall@pda.org

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

EXECUTIVE STAFF

Richard Johnson
President & CEO

David Talmage
Sr. VP, Education

Tina Morris, PhD
VP, Scientific & Regulatory Affairs

Jennifer Bell
VP, Finance

Debbie Goldstein
VP, Marketing

David Hall
VP, Sales

Falk Klar, PhD
VP, PDA Europe

Molly Moir
VP, Programs & Meetings

Trevor Swan
Director, Membership & Chapters

PDA BOARD OF DIRECTORS

OFFICERS

Chair | Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect | Jette Christensen, PhD
Novo Nordisk

Treasurer | Michael Sadowski
Baxter Healthcare

Secretary | Steven Lynn
Lynn Consulting

Imm. Past Chair | Martin VanTrieste
Civica Rx

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Joyce Bloomfield

Bettine Boltres, PhD
West

Veronique Davoust
Pfizer

Ghada Haddad
Merck

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates
Lachman Consultant Services, Inc.

Emma Ramnarine
Genentech/Roche

Anil Sawant, PhD
Merck & Co./Merck Sharp & Dohme

Melissa Seymour
Biogen

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org

PDA EUROPE — AM BORSIGTURM 60

Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org



26

Can We Reprogram the Human Computer?

CEO Jeff Galvin Believes We Can

Rebecca Stauffer, PDA

What if developers of cell and gene therapies treated their products like software releases? What if the human body could be manipulated like a highly complex computer?


Jeff Galvin, CEO of American Gene Technologies, certainly has that mindset, frequently referring to cell and gene therapies as “reprogramming the human computer.”

Kevin Allen Photography

Conference Puts Human Face on Cell and Gene Therapies

Rebecca Stauffer, PDA

Cell and gene therapies will unquestionably comprise a large part of biotech companies’ portfolios in the upcoming decades. Unlike traditional large molecules, these products have different manufacturing and supply chain needs, requiring a fresh look at existing regulations. Yet these challenges will need to be addressed due to the promise of these products to cure a variety of diseases and disorders.



30

InfoGraphic



34

Process Approach Goes Global

Earlier this year, the European arm of PDA’s Quality Systems Interest Group surveyed members of its process owner subgroup about how they have implemented the process approach at their companies.

The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—
contact the PDA Letter Managing Editor for details. © PDA 2019

PDA LETTER STAFF

Senior Director of Publishing
Walter Morris
(301) 656-5900, ext. 148
morris@pda.org

Managing Editor
Rebecca Stauffer
stauffer@pda.org

Graphic Designer
Katja Yount
yount@pda.org

PDA LETTER EDITORIAL COMMITTEE

Marcia Baroni
Eli Lilly & Company

Joanne Beck
Celgene

Walid El Azab
STERIS

Mirko Gabriele
Patheon

Stephanie Gaulding
Pharmatech Associates

Richard Hameister
Coherus Biosciences

Brian Hawkins, PhD
Pluristyx Inc.

Tamer Helmy, PhD
Alcon

Zena Kaufman
ZGK Quality Consulting

Gwendolyn Lohr
Novo Nordisk

Frank Matos
SOFIE

Aaron Mertens
STERIS

Ajay Pazhayattil
Eurofins

Andiyanto Sutandar, PhD
HGP Asia Pte. Ltd.

Cecilia Turoff
Pfizer

Wendy Zwolenski Lambert
Novartis

Kelly Waldron
ValSource

ADVERTISING SALES

vice President, Sales
David Hall
(301) 656-5900 ext. 160
hall@pda.org

EXECUTIVE STAFF

Richard Johnson
President & CEO

David Talmage
Sr. VP, Education

Tina Morris, PhD
VP, Scientific & Regulatory Affairs

Jennifer Bell
VP, Finance

Debbie Goldstein
VP, Marketing

David Hall
VP, Sales

Falk Klar, PhD
VP, PDA Europe

Molly Moir
VP, Programs & Meetings

Trevor Swan
Director, Membership & Chapters

PDA BOARD OF DIRECTORS

OFFICERS

Chair | Rebecca Devine, PhD
Regulatory Consultant

Chair-Elect | Jette Christensen, PhD
Novo Nordisk

Treasurer | Michael Sadowski
Baxter Healthcare

Secretary | Steven Lynn
Lynn Consulting

Imm. Past Chair | Martin VanTrieste
Civica Rx

DIRECTORS

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Barbara M. Allen, PhD
Eli Lilly

Michael Blackton
Adaptimmune

Joyce Bloomfield

Bettine Boltres, PhD
West

Veronique Davoust
Pfizer

Ghada Haddad
Merck

Stephan Krause, PhD
AstraZeneca Biologics

Mary Oates
Lachman Consultant Services, Inc.

Emma Ramnarine
Genentech/Roche

Anil Sawant, PhD
Merck & Co./Merck Sharp & Dohme

Melissa Seymour
Biogen

Departments

News & Notes

- 8 First PDA Standard Out for Public Comment
- 9 PDA Launches Quality Culture Website

People

- 10 Volunteer Spotlight | Lisa Rutter
- 12 Chapter Update | Student Learns Firsthand About Industry
- 14 Photostream | Advanced Therapy Medicinal Products Conference; PDA Visitors
- 16 Publishing Intern Expands Horizons at PDA

Science

- 18 **Science Snapshot** | Interest Group **Corner**: Adventitious Virus Detection Tech IG Activities Prove Infectious at 2019 PDA Virus Safety Forum; **Journal Top 10**: Particulate Matter Papers in Top 5 of Most-Read PDA Journal Articles
- 19 **Technology Trend** | Avoid Unmixed Process Solutions

Regulatory

- 36 **Regulatory Snapshot** | PUPSIT and the Annex 1 Revision
- 42 **Comments** | Suggestions for FDA Voluntary Recalls Doc
- 44 Incorporating QRM into Cell and Gene Therapy Processes

Voices of PDA

- 46 **Voices of the Board** | Science and Tech Lead the Way

Digital Exclusives

> **On the Issue** | A Particulate Matter Lifecycle Approach in Harmony with <1790> 
Gateway Analytical's **Antonio Scatena** discusses USP <1790> at the 2019 PDA Visual Inspection Forum.

> **On the Issue** | Here They Come: Pharma Students 
Keck Graduate Institute Student **Lyanna Jauregui** discusses her poster at the 2019 PDA Annual Meeting with the Southern California Chapter's **Jason Kerr**.

> **Are Your RMM Organisms Reflective of Your Process?**
Find out how you validate your rapid method.

pda.org/letter

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org

PDA EUROPE — AM BORSIGTURM 60

Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org

30



FDA Takes Close Look at Innovation

Rebecca Stauffer, PDA

Industry 4.0. Artificial intelligence. Big data. Even continuous manufacturing. All of these new technologies will drive the future of pharmaceutical and biopharmaceutical manufacturing. Yet questions persist as to how the U.S. FDA and other global regulatory agencies will address these new technologies, leaving some companies reluctant to fully embrace these advances as early adopters.

Cover Photo by Christopher Ames

34



Robotics and Big Data Key to Lab of the Future

Peter Crane, Synthace

I had the good fortune to attend the *Digital Robot Pharma Fab* workshop and the 4th PDA Europe Annual Meeting in Amsterdam this past June.

Add Sherlock Holmes to Your Investigation Team

The Role of a Microbiologist in Teams Investigating Product Failures Due to Manufacturing Issues

Tony Cundell, PhD, Microbiological Consulting, LLC


You have reported a microbial test failure to your site's management following confirmation by a laboratory investigation. You then assemble a cross-functional team to investigate the most likely cause of the failure during manufacturing.

38



InfoGraphic

42



Data Integrity: Remediation and Quality Culture

The 2019 *Data Integrity Workshop* opened with a real-time survey of attendees, the majority representing pharma/biopharma manufacturing. Here are some highlights that pertain to remediation and quality culture.

The PDA Letter is published 10 times per year, exclusively for PDA members.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Subscriptions are not available.

Articles in the PDA Letter may be reproduced with permission—
contact the PDA Letter Managing Editor for details. © PDA 2019

PDA LETTER STAFF	EXECUTIVE STAFF
Senior Director of Publishing Walter Morris (301) 656-5900, ext. 148 morris@pda.org	Richard Johnson <i>President & CEO</i>
Managing Editor Rebecca Stauffer stauffer@pda.org	David Talmage <i>Sr. VP, Education</i>
Graphic Designer Katja Yount yount@pda.org	Tina Morris, PhD <i>VP, Scientific & Regulatory Affairs</i>
PDA LETTER EDITORIAL COMMITTEE	Jennifer Bell <i>VP, Finance</i>
Marcia Baroni <i>Eli Lilly & Company</i>	Debbie Goldstein <i>VP, Marketing</i>
Joanne Beck <i>Celgene</i>	David Hall <i>VP, Sales</i>
Walid El Azab <i>STERIS</i>	Falk Klar, PhD <i>VP, PDA Europe</i>
Mirko Gabriele <i>Patheon</i>	Molly Moir <i>VP, Programs & Meetings</i>
Stephanie Gaulding <i>Pharmatech Associates</i>	Trevor Swan <i>Director, Membership & Chapters</i>
Richard Hameister <i>Coherus Biosciences</i>	PDA BOARD OF DIRECTORS
Brian Hawkins, PhD <i>Pluristyx Inc.</i>	OFFICERS
Tamer Helmy, PhD <i>Alcon</i>	Chair Rebecca Devine, PhD <i>Regulatory Consultant</i>
Zena Kaufman <i>ZGK Quality Consulting</i>	Chair-Elect Jette Christensen, PhD <i>Novo Nordisk</i>
Gwendolyn Lohr <i>Novo Nordisk</i>	Treasurer Michael Sadowski <i>Baxter Healthcare</i>
Frank Matos <i>SOFIE</i>	Secretary Steven Lynn <i>Lynn Consulting</i>
Aaron Mertens <i>STERIS</i>	Imm. Past Chair Martin VanTrieste <i>Civica Rx</i>
Ajay Pazhayattil <i>Eurofins</i>	DIRECTORS
Andiyanto Sutandar, PhD <i>HGP Asia Pte. Ltd.</i>	Masahiro Akimoto <i>Otsuka Pharmaceutical Factory, Inc.</i>
Cecilia Turoff <i>Pfizer</i>	Barbara M. Allen, PhD <i>Eli Lilly</i>
Wendy Zwolenski Lambert <i>Novartis</i>	Michael Blackton <i>Adaptimmune</i>
Kelly Waldron <i>ValSource</i>	Joyce Bloomfield
	Bettine Boltres, PhD <i>West</i>
	Veronique Davoust <i>Pfizer</i>
	Ghada Haddad <i>Merck</i>
	Stephan Krause, PhD <i>AstraZeneca Biologics</i>
	Mary Oates <i>Lachman Consultant Services, Inc.</i>
	Emma Ramnarine <i>Genentech/Roche</i>
	Anil Sawant, PhD <i>Merck & Co./Merck Sharp & Dohme</i>
	Melissa Seymour <i>Biogen</i>

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Departments

News & Notes

- 10 PDA In the News
- 11 Call for Volunteers: Regional Editions of PDA Letter

People

- 12 Volunteer Spotlight | Karolyn Gale
- 14 Chapter Update | Life Science Panel Discusses Career Journeys
- 16 Photostream | 2019 PDA/FDA Joint Regional Conference

Science

- 20 Science Snapshot | How to Implement an Effective Big Data Strategy
- 22 Technology | How to Qualify Your Disinfectants
- 27 Tri-Spine Crab Now on Endangered List

Regulatory

- 45 Comments | PDA Responds to EMA Combo Product Reg; PDA Input on USP 2020-2025 Revision Cycle
- 48 An Inside Look at the 2019 PDA Quality Week
- 50 Get Your Data Integrity Basics Down for Success

Voices of PDA

- 54 Voices of the Board | 2019: A Global Launch for PDA

Digital Exclusives

- > Strategic Application of Advanced Analytics for CGT Development
Advanced analytical data can help ensure a stable pipeline of cell and gene therapy products and even address CMC issues.

pda.org/letter

PDA GLOBAL HEADQUARTERS

4350 East West Hwy., Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
info@pda.org
www.pda.org

PDA EUROPE — AM BORSIGTURM 60

Am Borsigturm 60
13507 Berlin, Germany
Tel: 49 30 4365508-0
Fax: +49 30 4365508-66
info-europe@pda.org

PDA TRAINING & RESEARCH INSTITUTE

4350 East West Hwy., Suite 150
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (240) 482-1659
info-tri@pda.org